Oppenheimer Maintains Outperform on Achieve Life Sciences, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois maintains an Outperform rating on Achieve Life Sciences (ACHV) but lowers the price target from $18 to $11.
May 13, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on Achieve Life Sciences but reduces the price target from $18 to $11.
While the reduction in price target could suggest a tempered outlook, the maintenance of an Outperform rating indicates continued confidence in the company's prospects. This mixed signal could lead to neutral short-term price movement as investors weigh the implications.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100